These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 19514172

  • 1. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
    Berchem G, Dewilde S, Mahassen P.
    Bull Soc Sci Med Grand Duche Luxemb; 2009; (1):7-9. PubMed ID: 19514172
    [Abstract] [Full Text] [Related]

  • 2. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA.
    J Clin Oncol; 2008 Aug 20; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, Kato T.
    Jpn J Clin Oncol; 2012 Aug 20; 42(8):742-7. PubMed ID: 22628612
    [Abstract] [Full Text] [Related]

  • 5. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B.
    Nat Rev Urol; 2011 Jan 20; 8(1):10-1. PubMed ID: 21116300
    [No Abstract] [Full Text] [Related]

  • 6. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb 26; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan 26; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma.
    Lamarca A, Feliu J, Barriuso J.
    Br J Cancer; 2012 Mar 13; 106(6):1246. PubMed ID: 22294185
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. New therapeutic options for renal cell carcinoma.
    Stadler W.
    Clin Adv Hematol Oncol; 2006 Jun 13; 4(6):429-30. PubMed ID: 16981664
    [No Abstract] [Full Text] [Related]

  • 18. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A, Sire M.
    Ann Oncol; 2009 May 13; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.